P008 Skin of Color Primer
DESCRIPTION
This session will provide a comprehensive and concise high-yield overview of common conditions seen in skin of color. Skin, hair, and nail conditions which either uniquely affect skin of color populations or which present differently in skin of color will be discussed. This will include inflammatory, neoplastic, pigmentary, and alopecic conditions and other high-yield common skin of color conditions. Discussion will include updates in pathogenesis, along with evaluation and management considerations. Complementary and alternative treatment approaches will also be discussed. Presentations will include unique cultural considerations and cultural competency in the delivery of care to diverse populations.
LEARNING OBJECTIVES
Improve diagnosing of dermatologic conditions in skin of color.
Select safe and effective treatment options for various conditions across diverse populations.
Identify cultural competency considerations in taking care of patients of color.
SCHEDULE
6:00 PM
Inflammatory Disorders
Nada Elbuluk, MD, FAAD
6:30 PM
Pigmentary Disorders
Tasneem Mohammad, MD, FAAD
7:00 PM
Scarring and Non-scarring Alopecia
Victoria Holloway Barbosa, MD, FAAD
7:30 PM
Question and Answer
Nada Elbuluk, MD, FAAD, Victoria Holloway Barbosa, MD, FAAD, Tasneem Mohammad, MD, FAAD
7:40 PM
Skin Cancer in Skin of Color
Rebecca Vasquez, MD, FAAD
8:00 PM
Complementary and Integrative Therapies in SOC
Raja Sivamani, MD, FAAD
8:25 PM
Cosmetic Procedures in skin of color
Nkemjika Ugonabo, MD, FAAD
8:45 PM
Question and Answer
Raja Sivamani, MD, FAAD, Rebecca Vasquez, MD, FAAD
SPEAKERS
Victoria Holloway Barbosa, MD, FAAD
Nada Elbuluk, MD, FAAD
University of Southern California
Tasneem Mohammad, MD, FAAD
Raja Sivamani, MD, FAAD
Nkemjika Ugonabo, MD, FAAD
Unionderm/Albert Einstein College of Medicine
Rebecca Vasquez, MD, FAAD
SPEAKER DISCLOSURES
Victoria Holloway Barbosa, MD, FAAD
Eli Lilly and Company – Advisory Board(Fees), Consultant(Fees); L'Oreal USA Inc. – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees), Other(Grants/Research Funding); Vichy Laboratoires – Advisory Board(Fees);
Nada Elbuluk, MD, FAAD
AbbVie – Advisory Board(Fees), Consultant (1099 relationship)(Fees); Avita Medical – Consultant (1099 relationship)(Fees); Beiersdorf – Advisory Board(Fees), Consultant (1099 relationship)(Fees), Speaker(Fees); Canfield Scientific, Inc. – Consultant (1099 relationship)(Fees); Dior – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Advisory Board(Fees); Galderma Laboratories, L.P. – Advisory Board(Fees); Global Vitiligo Foundation – Board of Directors(No Compensation Received); Incyte Corporation – Advisory Board(Fees), Consultant(Fees); Janssen Biotech – Advisory Board(Fees), Consultant (1099 relationship)(Fees); Kao USA – Consultant (1099 relationship)(Fees); Kenvue – Consultant (1099 relationship)(Fees); L'Oreal USA Inc. – Advisory Board(Fees); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Fees); McGraw-Hill Companies – Advisory Board(Fees), Other(Other Financial Benefit); Medscape – Speaker(Fees); Pfizer Inc. – Advisory Board(Fees), Investigator(Grants/Research Funding); Sanofi – Advisory Board(Fees); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); VisualDx – Consultant(Fees), Consultant(Stock Options); Women's Dermatologic Society – Board of Directors(No Compensation Received);
Tasneem Mohammad, MD, FAAD
Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); atheneum – Consultant(Honoraria); Avita – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Beiersdorf – Consultant (1099 relationship)(Fees); Beiersdorf, Inc. – Speaker(Honoraria); Clinuvel – Investigator(Grants/Research Funding); Disc Medicine – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Ferndale Laboratories, Inc. – Consultant (1099 relationship)(Honoraria); Guidepoint Global, LLC – Consultant(Honoraria); Immune Tolerance Network – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Kenvue – Consultant (1099 relationship)(Honoraria); Medscape – Speaker/Faculty Education(Honoraria); Mitsubishi Tanabe Pharma Corporation – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); polaris health – Speaker/Faculty Education(Honoraria); Third Bridge – Consultant (1099 relationship)(Honoraria); VeraDermics Inc. – Consultant (1099 relationship)(Honoraria);
Raja Sivamani, MD, FAAD
AbbVie – Speaker(Honoraria); Almirall – Speaker(Honoraria); Arbonne – Advisory Board(Fees); Bristol Myers Squibb – Speaker(Honoraria); Burt's Bees – Consultant(Fees); Codex Labs – Advisory Board(Fees); Eli Lilly – Speaker(Honoraria); Image Skincare – Advisory Board(Honoraria); Incyte Corporation – Speaker(Honoraria); LEO Laboratories Ltd (LEO Pharma) – Speaker(Honoraria); Novartis – Advisory Board(Honoraria); Nutrafol – Advisory Board(Honoraria); Pfizer Inc. – Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Speaker(Honoraria); Sanofi Genzyme – Speaker(Honoraria); Trace Minerals – Advisory Board(Honoraria);
Nkemjika Ugonabo, MD, FAAD
No financial relationships exist with ineligible companies.
Rebecca Vasquez, MD, FAAD
Incyte – Consultant (1099 relationship)(Honoraria);